Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2013 Mar 14;131(6):10.1016/j.jaci.2013.01.034. doi: 10.1016/j.jaci.2013.01.034

TABLE V.

Comparison of AUCs of symptoms scores between episodes that received and did not receive OCSs (MIST cohort)

Outcome Episode severity level* No. Episodes that were not treated
with OCSs (n = 585)
Episodes that were treated
with OCSs (n = 161)
Pvalue
AUC total symptoms score Less severe episodes 613 4.4 (0.18) 4.8 (0.24) .18
More severe episodes 133 4.6 (0.36) 4.9 (0.34) .46
AUC cough score Less severe episodes 613 3.0 (0.11) 3.2 (0.17) .26
More severe episodes 133 3.1 (0.22) 3.2 (0.22) .83
AUC wheeze score Less severe episodes 613 1.5 (0.11) 1.8 (0.14) .01
More severe episodes 133 1.6 (0.23) 2.1 (0.20) .05
AUC trouble breathing score Less severe episodes 613 1.7 (0.11) 1.9 (0.13) .25
More severe episodes 133 1.9 (0.22) 2.0 (0.19) .76
AUC interference with activity score Less severe episodes 613 1.6 (0.11) 1.8 (0.14) .36
More severe episodes 133 1.5 (0.21) 1.6 (0.20) .53

Data are stratified based on the episode’s severity: less severe episodes (n = 613) and more severe episodes (n = 133). The square root transformation was applied to all AUCs to improve the approximate normality of the AUC measurements. Data are represented as means (SEs) of the square root of AUCs. All comparisons were adjusted for maximum propensity score (natural log) along with correlation among repeated measurements.

*

Episode severity was defined based on a propensity score of greater than or less than 0.2.